These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 37022666

  • 1. Efanesoctocog Alfa: First Approval.
    Keam SJ.
    Drugs; 2023 May; 83(7):633-638. PubMed ID: 37022666
    [Abstract] [Full Text] [Related]

  • 2. Efanesoctocog alfa for the prevention and treatment of bleeding in patients with hemophilia A.
    Konkle BA.
    Expert Rev Hematol; 2023 May; 16(8):567-573. PubMed ID: 37289594
    [Abstract] [Full Text] [Related]

  • 3. Efanesoctocog alfa: the renaissance of Factor VIII replacement therapy.
    Dargaud Y, Leuci A, Ruiz AR, Lacroix-Desmazes S.
    Haematologica; 2024 Aug 01; 109(8):2436-2444. PubMed ID: 38356459
    [Abstract] [Full Text] [Related]

  • 4. Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A.
    von Drygalski A, Chowdary P, Kulkarni R, Susen S, Konkle BA, Oldenburg J, Matino D, Klamroth R, Weyand AC, Jimenez-Yuste V, Nogami K, Poloskey S, Winding B, Willemze A, Knobe K, XTEND-1 Trial Group.
    N Engl J Med; 2023 Jan 26; 388(4):310-318. PubMed ID: 36720133
    [Abstract] [Full Text] [Related]

  • 5. Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A.
    Malec L, Peyvandi F, Chan AKC, Königs C, Zulfikar B, Yuan H, Simpson M, Álvarez Román MT, Carcao M, Staber JM, Dunn AL, Chou SC, d'Oiron R, Albisetti M, Demissie M, Santagostino E, Yarramaneni A, Wong N, Abad-Franch L, Gunawardena S, Fijnvandraat K, XTEND-Kids Trial Group.
    N Engl J Med; 2024 Jul 18; 391(3):235-246. PubMed ID: 39018533
    [Abstract] [Full Text] [Related]

  • 6. Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII.
    Demers M, Aleman MM, Kistanova E, Peters R, Salas J, Seth Chhabra E.
    J Thromb Haemost; 2022 Jul 18; 20(7):1674-1683. PubMed ID: 35466511
    [Abstract] [Full Text] [Related]

  • 7. Periprocedural management of type 2N von Willebrand disease with efanesoctocog alfa.
    Ryu JH, Bauer KA, Schulman S.
    J Thromb Haemost; 2023 Dec 18; 21(12):3508-3510. PubMed ID: 37734716
    [Abstract] [Full Text] [Related]

  • 8. Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study.
    Lissitchkov T, Willemze A, Katragadda S, Rice K, Poloskey S, Benson C.
    Blood Adv; 2022 Feb 22; 6(4):1089-1094. PubMed ID: 34794179
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic evaluation of efanesoctocog alfa: breakthrough factor VIII therapy for hemophilia A.
    Yada K, Nogami K.
    Expert Opin Drug Metab Toxicol; 2024 Oct 04; ():1-10. PubMed ID: 39323385
    [Abstract] [Full Text] [Related]

  • 10. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients.
    Klukowska A, Windyga J, Batorova A.
    Thromb Res; 2011 Mar 04; 127(3):247-53. PubMed ID: 21220152
    [Abstract] [Full Text] [Related]

  • 11. Lonoctocog Alfa: A Review in Haemophilia A.
    Al-Salama ZT, Scott LJ.
    Drugs; 2017 Oct 04; 77(15):1677-1686. PubMed ID: 28900904
    [Abstract] [Full Text] [Related]

  • 12. A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one-stage clotting and chromogenic substrate assays at clinical haemostasis laboratories.
    Pipe S, Sadeghi-Khomami A, Konkle BA, Kitchen S, Negrier C, Liu M, Santagostino E, Willemze A, Abad-Franch L, Knobe K, Seth Chhabra E.
    Haemophilia; 2024 Jan 04; 30(1):214-223. PubMed ID: 37902390
    [Abstract] [Full Text] [Related]

  • 13. Plasma Clearance of Coagulation Factor VIII and Extension of Its Half-Life for the Therapy of Hemophilia A: A Critical Review of the Current State of Research and Practice.
    Sarafanov AG.
    Int J Mol Sci; 2023 May 11; 24(10):. PubMed ID: 37239930
    [Abstract] [Full Text] [Related]

  • 14. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
    Hartholt RB, van Velzen AS, Peyron I, Ten Brinke A, Fijnvandraat K, Voorberg J.
    Blood Rev; 2017 Sep 11; 31(5):339-347. PubMed ID: 28716211
    [Abstract] [Full Text] [Related]

  • 15. Efmoroctocog Alfa: A Review in Haemophilia A.
    Frampton JE.
    Drugs; 2016 Sep 11; 76(13):1281-1291. PubMed ID: 27487799
    [Abstract] [Full Text] [Related]

  • 16. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.
    Federici AB, Baudo F, Caracciolo C, Mancuso G, Mazzucconi MG, Musso R, Schinco PC, Targhetta R, Mannuccio Mannucci P.
    Haemophilia; 2002 Nov 11; 8(6):761-7. PubMed ID: 12410644
    [Abstract] [Full Text] [Related]

  • 17. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice.
    Seth Chhabra E, Liu T, Kulman J, Patarroyo-White S, Yang B, Lu Q, Drager D, Moore N, Liu J, Holthaus AM, Sommer JM, Ismail A, Rabinovich D, Liu Z, van der Flier A, Goodman A, Furcht C, Tie M, Carlage T, Mauldin R, Dobrowsky TM, Liu Z, Mercury O, Zhu L, Mei B, Schellenberger V, Jiang H, Pierce GF, Salas J, Peters R.
    Blood; 2020 Apr 23; 135(17):1484-1496. PubMed ID: 32078672
    [Abstract] [Full Text] [Related]

  • 18. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U.
    Clin Appl Thromb Hemost; 2007 Jan 23; 13(1):14-34. PubMed ID: 17164493
    [Abstract] [Full Text] [Related]

  • 19. Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice.
    Vollack-Hesse N, Oleshko O, Werwitzke S, Solecka-Witulska B, Kannicht C, Tiede A.
    Blood; 2021 Feb 25; 137(8):1072-1081. PubMed ID: 32877516
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa.
    Lissitchkov T, Willemze A, Jan C, Zilberstein M, Katragadda S.
    Res Pract Thromb Haemost; 2023 May 25; 7(4):100176. PubMed ID: 37538505
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.